Results 41 to 50 of about 203,760 (190)

Characteristics and Outcomes of Mavacamten Use in 2440 Patients With Obstructive Hypertrophic Cardiomyopathy

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Our objective was to assess real‐world outcomes and health care use associated with commercial mavacamten use in patients with obstructive hypertrophic cardiomyopathy.
Ingy Mahana   +7 more
doaj   +1 more source

Acute Left Ventricular Ballooning: Tools to Differentiate Hypertrophic Cardiomyopathy with Outflow Obstruction from Neurohumoral Takotsubo Syndrome

open access: yesReviews in Cardiovascular Medicine, 2023
Despite considerable interest in the syndrome of acute left ventricular (LV) ballooning, its pathophysiology has remained ill-defined. In this review, we explore observational data describing two etiologies of acute LV ballooning: neurohumoral classic ...
Arushi Singh   +3 more
doaj   +1 more source

Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy [PDF]

open access: yes, 2002
Background-Although studies have suggested that "late-onset" hypertrophic cardiomyopathy (HCM) may be caused by sarcomeric protein gene mutations, the cause of HCM in the majority of patients is unknown.
Tei, C   +13 more
core  

Echocardiographic Changes Following Surgical Myectomy in Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy: Insights From the SPIRIT‐HCM Study

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background In obstructive hypertrophic cardiomyopathy, myectomy improves symptoms, quality of life, and left ventricular (LV) outflow tract gradients. We prospectively evaluated the temporal changes in various echo parameters after myectomy.
Milind Y. Desai   +10 more
doaj   +1 more source

Heart disease in infants of diabetic mothers [PDF]

open access: yes, 2000
Congenital anomalies occur more commonly in infants born to diabetic mothers, and cardiac defects predominate. Although respiratory problems are also frequently found in those infants, they need to be differentiated from cardiovascular problems that ...
Narchi, Hassib, Kulaylat, N.
core  

Disopyramide Revisited for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy: Efficacy and Safety in Patients Treated for at Least 5 Years

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Disopyramide is used to treat heart failure symptoms in patients with obstructive hypertrophic cardiomyopathy (HCM) with known medium‐term efficacy and safety, while long‐term outcomes are unknown. Methods and Results A total of 92 consecutive
Daniele Massera   +9 more
doaj   +1 more source

Differences in microRNA-29 and Pro-fibrotic Gene Expression in Mouse and Human Hypertrophic Cardiomyopathy

open access: yesFrontiers in Cardiovascular Medicine, 2019
Background: Hypertrophic cardiomyopathy (HCM) is characterized by myocyte hypertrophy and fibrosis. Studies in two mouse models (R92W-TnT/R403Q-MyHC) at early HCM stage revealed upregulation of endothelin (ET1) signaling in both mutants, but TGFβ ...
Yamin Liu   +17 more
doaj   +1 more source

The clinical characteristics of families with hypertrophic cardiomyopathy associated with mutations of cardiac myosin binding protein C [PDF]

open access: yes, 2010
Introduction: Mutations in cardiac myosin binding protein-C (MYBPC3), the most common genetic cause of hypertrophic cardiomyopathy (HCM), have been reported to cause a comparatively benign and late-onset form of the disease with incomplete penetrance ...
Page, S.P.
core  

Self- and Goal-Directed Valsalva Maneuver vs Exercise in Eliciting Left Ventricular Outflow Tract Obstruction

open access: yesJACC: Advances
Background: In symptomatic patients with hypertrophic cardiomyopathy (HCM), eliciting left ventricular outflow tract obstruction (LVOTO) is critical. A self-directed Valsalva (SDV) and exercise (EX) are frequent tools used to unmask obstruction in HCM ...
Aakash Bavishi, MD, MSCI   +9 more
doaj   +1 more source

Syndrome of Reversible Cardiogenic Shock and Left Ventricular Ballooning in Obstructive Hypertrophic Cardiomyopathy

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background Cardiogenic shock from most causes has unfavorable prognosis. Hypertrophic cardiomyopathy (HCM) can uncommonly present with apical ballooning and shock in association with sudden development of severe and unrelenting left ventricular (LV ...
Mark V. Sherrid   +13 more
doaj   +1 more source

Home - About - Disclaimer - Privacy